File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/COC.0b013e318074f916
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Response to neoadjuvant chemotherapy and hormonotherapy in Chinese women with breast cancer
Title | Response to neoadjuvant chemotherapy and hormonotherapy in Chinese women with breast cancer |
---|---|
Authors | |
Issue Date | 2007 |
Publisher | Lippincott Williams & Wilkins. |
Citation | The 17th Annual National Interdisciplinary Breast Center Conference: Breast Center Evolution: 2007 and Beyond. In American Journal of Clinical Oncology, 2007, v. 30 n. 4, p. 455-456, abstract no. 32 How to Cite? |
Abstract | OBJECTIVES: There is an increase use of neoadjuvant chemo-hormonotherapy in the management of breast cancer in the past years. A variety of treatment regimens resulted in different efficacy and tolerability. This study aims to review the local experience of using such modality in a university breast surgical center. METHODS: A retrospective study of patients with breast cancer who received neoadjuvant chemotherapy or hormonal therapy followed by definitive surgery from January 2002 to December 2006 was performed. RESULTS: 91 patients received neoadjuvant chemotherapy during the study period. 53 patients received anthracycline-based regimen (AC only), 37 patients anthracycline and taxane-based regimen (AC + T) and 1 patient had additional Trastuzumab after receiving anthracycline and taxane (AC + TH). The pathologic complete response rates of AC only, AC + T and AC + TH were 9.4% (5/53), 24.3% (9/37) and 100.0% (1/1), respectively. Number of cycles and tumor size were significant factors affecting the pCR rate after neoadjuvant chemotherapy. Grade 4 toxicity was observed in 12.2% of patients during AC treatment and in 15.8% of patients during docetaxel treatment. 81 patients received aromatase inhibitors (AI) as neoadjuvant hormonal therapy. The pCR rate of AI was 1.2% (1/81) and none of the patients experienced grade 3 or 4 toxicity. CONCLUSIONS: The efficacy and tolerability of neoadjuvant therapy are similar in our population as compared with the Western countries. Neoadjuvant chemotherapy could achieve a higher response rate but neoadjuvant hormonotherapy was better tolerated. |
Persistent Identifier | http://hdl.handle.net/10722/182313 |
ISSN | 2023 Impact Factor: 1.6 2023 SCImago Journal Rankings: 0.711 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suen, DTK | - |
dc.contributor.author | Kwong, A | - |
dc.date.accessioned | 2013-04-22T01:33:14Z | - |
dc.date.available | 2013-04-22T01:33:14Z | - |
dc.date.issued | 2007 | - |
dc.identifier.citation | The 17th Annual National Interdisciplinary Breast Center Conference: Breast Center Evolution: 2007 and Beyond. In American Journal of Clinical Oncology, 2007, v. 30 n. 4, p. 455-456, abstract no. 32 | - |
dc.identifier.issn | 0277-3732 | - |
dc.identifier.uri | http://hdl.handle.net/10722/182313 | - |
dc.description.abstract | OBJECTIVES: There is an increase use of neoadjuvant chemo-hormonotherapy in the management of breast cancer in the past years. A variety of treatment regimens resulted in different efficacy and tolerability. This study aims to review the local experience of using such modality in a university breast surgical center. METHODS: A retrospective study of patients with breast cancer who received neoadjuvant chemotherapy or hormonal therapy followed by definitive surgery from January 2002 to December 2006 was performed. RESULTS: 91 patients received neoadjuvant chemotherapy during the study period. 53 patients received anthracycline-based regimen (AC only), 37 patients anthracycline and taxane-based regimen (AC + T) and 1 patient had additional Trastuzumab after receiving anthracycline and taxane (AC + TH). The pathologic complete response rates of AC only, AC + T and AC + TH were 9.4% (5/53), 24.3% (9/37) and 100.0% (1/1), respectively. Number of cycles and tumor size were significant factors affecting the pCR rate after neoadjuvant chemotherapy. Grade 4 toxicity was observed in 12.2% of patients during AC treatment and in 15.8% of patients during docetaxel treatment. 81 patients received aromatase inhibitors (AI) as neoadjuvant hormonal therapy. The pCR rate of AI was 1.2% (1/81) and none of the patients experienced grade 3 or 4 toxicity. CONCLUSIONS: The efficacy and tolerability of neoadjuvant therapy are similar in our population as compared with the Western countries. Neoadjuvant chemotherapy could achieve a higher response rate but neoadjuvant hormonotherapy was better tolerated. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. | - |
dc.relation.ispartof | American Journal of Clinical Oncology | - |
dc.title | Response to neoadjuvant chemotherapy and hormonotherapy in Chinese women with breast cancer | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Kwong, A: avakwong@hkucc.hku.hk | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/COC.0b013e318074f916 | - |
dc.identifier.hkuros | 137435 | - |
dc.identifier.volume | 30 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 455, abstract no. 32 | - |
dc.identifier.epage | 456 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0277-3732 | - |